Pharmacological treatment with psychostimulants is the most widely studied treatment for ADHD. Core to this therapeutic strategy would be to develop a product with mechanisms of action that would both increase the release of dopamine, and induce long term D 2 receptor proliferation. While the genetics are far more complex than these genes, carriers of dopaminergic gene variants, or genetic deficits including these or other gene subsets, can develop behavioral manifestations of RDS. Children have messy rooms; adults have cluttered desks; daily activities tend to be chaotic. In this regard, Larsson et al suggested that the finding of persistent cross-subtype ie, combined and persistent subtype-specific genetic influences ie, primarily hyperactive-impulsive and inattentive disorders are in line with a genetic basis for the DSM-IV classification of ADHD subtypes Table 1.
The dopamine transporter is responsible for moving dopamine across the presynaptic membrane back into the nerve cell from which it was released.
Attention-deficit-hyperactivity disorder and reward deficiency syndrome
Little is known about the risks and characteristics of ADHD patients who misuse or divert their stimulant medications. In individuals not possessing the variant in the dopamine receptor gene, but who have engaged in risky behaviors such as cocaine abuse, extremely low caloric diet, high levels of stress over an extended period of timethe brain functions as though it had the DRD 2 genetic variant or other specific gene variants Faraone In contrast, 2-month treatment with methylphenidate started also at adolescence decreased D 2 R availability, which could raise concern that at this life stage, short treatments could possibly increase vulnerability to drug abuse during adulthood. The latest version of this test is computerized, and it is designed to identify a minimum of four types of attention failures. Don't see what you're looking for?